The upregulation of RUNX2 was verified in the cirrhosis, NAFLD, NASH and HBV‐related fibrosis datasets (Figure 1J; Figure S2G–I, Supporting Information). Here, RUNX2 is linked to metabolic dysfunction-associated steatotic liver disease.